A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma

Blood

Volumn 129, Issue 25, 2017, Pages 3294-3303

  Martin, Thomas ^a   Baz, Rachid ^b   Benson, Don M ^c   Lendvai, Nikoletta ^d,e   Wolf, Jeffrey ^a   Munster, Pamela ^a   Lesokhin, Alexander M ^d,e   Wack, Claudine ^f   Charpentier, Eric ^g   Campana, Frank ^g   Vij, Ravi ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f SANOFI   (France)

^g Sanofi Oncology Development   (Canada)

^h WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; ISATUXIMAB; LENALIDOMIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; MONOCLONAL ANTIBODY; THALIDOMIDE;

ADOLESCENT; AGED; ANAPHYLAXIS; ANEMIA; ARTICLE; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COUGHING; CYTOGENETICS; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FACE EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INFUSION RELATED REACTION; INSOMNIA; LEUKOPENIA; LUNG EMBOLISM; LUNG INFECTION; LYMPHOCYTOPENIA; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE SPASM; NAUSEA; NEUTROPENIA; NOSE OBSTRUCTION; OPEN STUDY; OPERATIVE BLOOD LOSS; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SEPSIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ADULT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; TUMOR RECURRENCE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEXAMETHASONE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; THALIDOMIDE;

EID: 85021632881     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-09-740787     Document Type: Article

References (43)

1. Rajkumar SV. Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma? Hematology Am Soc Hematol Educ Program. 2012;2012: 354-361.
2. Eshaghian S, Berenson JR. Multiple myeloma: improved outcomes with new therapeutic approaches. Curr Opin Support Palliat Care. 2012;6(3): 330-336.
3. Palumbo A, Hajek R, Delforge M, et al; MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19): 1759-1769.
4. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5): 2516-2520.
5. San-Miguel JF, Hungria VT, Yoon SS, et al. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematol. 2016; 3(11): e506-e515.
6. Siegel DS, Dimopoulos M, Jagannath S, et al. VANTAGE 095: an international, multicenter, open-label study of vorinostat (MK-0683) in combination with bortezomib in patients with relapsed and refractory mulltiple myeloma. Clin Lymphoma Myeloma Leuk. 2016;16(6): 329-334.
7. Kumar SK, Lee JH, Lahuerta JJ, et al; International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter International Myeloma Working Group study [published correction appears in Leukemia. 2012;26(5): 1153]
8. Leukemia. 2012; 26(1): 149-157.
9. Moreau P, Masszi T, Grzasko N, et al; TOURMALINE-MM1 Study Group. Oral ixazomib, lenalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17): 1621-1634.
10. Janssen Biotech, Inc. Highlights of prescribing information: DARALEX (daratumumab) injection, for intravenous use. http: //www.accessdata.fda.gov/drugsatfda_docs/label/2016/761036s004lbl. pdf. Accessed 30 January 2017.
11. Darzalex: EPAR–Summary of Product Characteristics. http: //www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Product_Information/human/004077/ WC500207296.pdf. Accessed 30 January 2017.
12. Bristol-Myers Squibb Company. Highlights of prescribing information: EMPLICITI (elotuzumab) for injection, for intravenous use. Available at: https: //www.accessdata.fda.gov/ drugsatfda_docs/label/2015/761035s000lbl.pdf. Accessed 30 January 2017.
13. Empliciti: EPAR–Summary of Product Characteristics. http: //www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003967/ WC500206673.pdf. Accessed 30 January 2017.
14. Lonial S, Kaufman J, Reece D, Mateos MV, Laubach J, Richardson P. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma. Expert Opin Biol Ther. 2016;16(10): 1291-1301.
15. Lonial S, Dimopoulos M, Palumbo A, et al; ELOQUENT-2 Investigators. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7): 621-631.
16. Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027): 1551-1560.
17. Palumbo A, Chanan-Khan A, Weisel K, et al; CASTOR Investigators. Daratumumab, bortezomib and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8): 754-766.
18. Dimopoulos MA, Oriol A, Nahi H, et al; POLLUX Investigators. Daratumumab, lenalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14): 1319-1331.
19. Roguska MA, Pedersen JT, Keddy CA, et al. Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc Natl Acad Sci USA. 1994;91(3): 969-973.
20. Deckert J, Wetzel MC, Bartle LM, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD381 hematologic malignancies. Clin Cancer Res. 2014;20(17): 4574-4583.
21. Martin T, Richter J, Vij R, et al. A dose finding phase II trial of isatuximabtuximab (SAR650984, anti-CD38 mAb) as a single agent in relapsed/ refractory multiple myeloma [abstract]. Blood. 2015;126(23). Abstract 509.
22. Durie BG, Harousseau JL, Miguel JS, et al; International Myeloma Working Group. International uniform response criteria for multiple myeloma [published correction appears in Leukemia. 2006;21: 1134
23. Leukemia. 2006;20 (12): 2220
24. Leukemia. 2006;20(9): 1467-1473.
25. Hann B, Cai T, Wang D, et al. SAR650984, an anti-CD38 antibody, shows anti-tumor activity in a preclinical model of multiple myeloma. In: Proceedings from the American Association for Cancer Research (AACR) Annual Meeting; 6-10 April 2013; Washington, DC. Poster No. 5469.
26. Xu Y, Sun J, Sheard MA, et al. Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFb1. Cancer Immunol Immunother. 2013;62(10): 1637-1648.
27. Mitsiades CS, Chen-Kiang S. Immunomodulation as a therapeutic strategy in the treatment of multiple myeloma. Crit Rev Oncol Hematol. 2013; 88(suppl 1): S5-S13.
28. Chan AC, Neeson P, Leeansyah E, et al. Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy. Clin Exp Immunol. 2014;175(1): 49-58.
29. Rajkumar SV, Harousseau JL, Durie B, et al; International Myeloma Workshop Consensus Panel 1. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18): 4691-4695.
30. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist. 2007;12(5): 601-609.
31. João C, Coelho I, Costa C, Esteves S, Lucio P. Efficacy and safety of lenalidomide in relapse/ refractory multiple myeloma–real life experience of a tertiary cancer center. Ann Hematol. 2015; 94(1): 97-105.
32. Dimopoulos MA, Swern AS, Li JS, et al. Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood Cancer J. 2014;4: e257.
33. Yang B, Yu RL, Chi XH, Lu XC. Lenalidomide treatment for multiple myeloma: systematic review and meta-analysis of randomized controlled trials. PLoS One. 2013;8(5): e64354.
34. Dimopoulos M, Spencer A, Attal M, et al; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21): 2123-2132.
35. Weber DM, Chen C, Niesvizky R, et al; Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007; 357(21): 2133-2142.
36. Stewart AK, Rajkumar SV, Dimopoulos MA, et al; ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2): 142-152.
37. San Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(11): 1055-1066.
38. Richardson PG, Jagannath S, Moreau P, et al; 1703 study investigators. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015;2(12): e516-e527.
39. Plesner T, Arkenau H-T, Gimsing P, et al. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood. 2016;128: 1821-1828.
40. Usmani SZ, Dimopoulos M, Belch A, et al. Efficacy of daratumumab, lenalidomide, and dexamethasone vs lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients with 1 to 3 prior lines of therapy: updated analysis of POLLUX [abstract]. Blood. 2016;128(22). Abstract 1151.
41. Martin T, Strickland S, Glenn M, Hsu K, Charpentier E, Mikhael J. A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma. In: Proceedings from the American Society of Clinical Oncology (ASCO) Annual Meeting; 30 May-3 June 2014; Chicago, IL. Poster No. 8532.
42. Celgene Corporation. REVLIMID 5 AND 10 mg capsules: Clinical pharmacology and biopharmaceutics NDA review. http: //www.accessdata.fda.gov/drugsatfda_docs/nda/2005/ 021880s000_Revlimid_BioPharmR.pdf. Accessed 22 June 2016.
43. Vij R, Lendvai N, Martin TG, et al. A phase 1b dose escalation trial of isatuximab (SAR650984, anti-CD38 mAb) plus lenalidomide and dexamethasone (Len/Dex) in relapsed/refractory MM (RRMM): interim results from two new dose cohorts. In: Proceedings from the American Society of Clinical Oncology (ASCO) Annual Meeting; 3-7 June 2016; Chicago, IL. Abstract 8009.